Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.
Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).
Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.
Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.
Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115 .